BiondVax Pharmaceuticals ... (BVXV)
NASDAQ: BVXV
· Real-Time Price · USD
1.36
0.01 (0.74%)
At close: Sep 06, 2023, 9:59 PM
Company Description
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel.
The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.
The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
BiondVax Pharmaceuticals Ltd.
| Country | IL |
| IPO Date | May 12, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Amir Reichman |
Contact Details
Address: Jerusalem BioPark Building Jerusalem, IL | |
| Website | https://www.biondvax.com |
Stock Details
| Ticker Symbol | BVXV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001611747 |
| CUSIP Number | 09073Q105 |
| ISIN Number | US09073Q1058 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Amir Reichman M.B.A., M.Sc. | Chief Executive Officer & Director |
| Elad Mark B.Sc., Eng., M.B.A. | Chief Operating Officer |
| Uri Ben-Or C.P.A., CPA, M.B.A., MBA | Chief Financial Officer |
| Uri Ben-Or CPA, CPA, M.B.A., MBA | Chief Financial Officer |
| Dalit Weinstein Fischer | Vice President and Head of Technical R&D |
| Dr. Tamar Ben-Yedidia Ph.D. | Chief Science Officer |
| Joshua E. Phillipson B.Sc., M.B.A. | Director of Communications & Investor Relations |
| Moran Ahdout Fruchter L.L.B. | Chief of Staff |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 12, 2025 | 6-K | Filing |
| Jun 05, 2025 | 424B3 | Filing |
| Jun 05, 2025 | 6-K | Filing |
| Jun 02, 2025 | 6-K | Filing |
| May 12, 2025 | POS AM | Filing |
| May 07, 2025 | 20-F | Filing |
| Apr 29, 2025 | NT 20-F | Filing |
| Mar 27, 2025 | 6-K | Filing |
| Mar 26, 2025 | SCHEDULE 13G | Filing |
| Mar 24, 2025 | 6-K | Filing |